Streetbeat News

Revenues

TCBI

Texas Capital Bancshares (NASDAQ:TCBI) has received mixed reviews from 10 analysts over the last three months, with ratings ranging from bullish to bearish. The average 12-month price target is now $66.00, down from $68.25, indicating a negative sentiment shift. Financial challenges such as a -11.16% revenue decline, below-average net margin, ROE, and ROA, along with a high debt-to-equity ratio, suggest operational and profitability hurdles. The company operates in major Texas metropolitan areas and specializes in secured lending.

Portfolio Pulse from Benzinga Insights

April 01, 2024 | 12:02 pm

COHR

Analysts have recently updated their ratings and price targets for Coherent (NYSE:COHR), showing a predominantly bullish outlook. Over the past three months, 11 analysts have provided insights, with the latest updates indicating an increase in the average 12-month price target to $63.82 from $48.00, a 32.96% rise. The adjustments reflect positive sentiment based on Coherent's market position and performance, despite a revenue decline of -17.43% as of December 31, 2023, and challenges in revenue growth compared to industry peers. The company's net margin and return on equity and assets outperform industry averages, but its high debt-to-equity ratio of 0.8 raises financial leverage concerns.

Portfolio Pulse from Benzinga Insights

April 01, 2024 | 12:02 pm

LEGN

Legend Biotech (NASDAQ:LEGN) received mixed analyst ratings with a shift towards bullish sentiment in the last quarter. The average 12-month price target was raised to $86.33 from $84.50, indicating a positive outlook. Analysts from firms like HC Wainwright & Co., UBS, Raymond James, RBC Capital, and Barclays adjusted their ratings and price targets, reflecting optimism about Legend Biotech's future performance. The company, engaged in novel cell therapies for oncology, showed a significant revenue growth rate of 187.57% as of December 31, 2023, but struggles with profitability and efficiency metrics.

Portfolio Pulse from Benzinga Insights

April 01, 2024 | 12:01 pm

FTI

Five analysts have recently updated their evaluations of TechnipFMC (NYSE:FTI), showing a mix of bullish to indifferent sentiments. The average 12-month price target has risen to $28.72, indicating a positive outlook. TechnipFMC, a leading offshore service provider, has shown a revenue growth of 22.62% and operates with a lower than industry average debt-to-equity ratio. However, its net margin and returns on equity and assets are below industry benchmarks.

Portfolio Pulse from Benzinga Insights

April 01, 2024 | 12:01 pm

LII

Lennox Intl (NYSE:LII) received mixed analyst ratings, with recent evaluations showing a bullish trend. The average 12-month price target is $462.4, marking an 8.67% increase from the previous target. Analysts from firms like Mizuho, TD Cowen, RBC Capital, JP Morgan, and Deutsche Bank have adjusted their ratings and price targets, reflecting changes in market conditions and company performance. Lennox Intl, a manufacturer and distributor of HVAC and refrigeration products, has shown strong financial health with a notable revenue growth rate of 5.58%, a net margin of 12.51%, and an ROE of 64.97%, despite a high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

April 01, 2024 | 12:00 pm

VIAV

Viavi Solutions (NASDAQ:VIAV) has been evaluated by 5 analysts over the last three months, showing a diverse range of opinions. Recent updates include raised price targets and ratings, with an average 12-month price target now at $14.00, up 25% from $11.20. The company's financials indicate challenges in revenue growth and ROE, but strengths in net margin, ROA, and debt management.

Portfolio Pulse from Benzinga Insights

April 01, 2024 | 12:00 pm

SYPR

Sypris Solutions has revised its 2024 revenue growth forecast to 10%-15% year-over-year, down from the previously expected 15%-20%. Despite the adjustment, the company maintains a positive outlook due to strong backlog and new contract awards. Gross profit is anticipated to rise by 20%-25%, with gross margins expanding by 150-175 basis points.

Portfolio Pulse from Benzinga Newsdesk

April 01, 2024 | 11:51 am

OCUP

VTRS

Ocuphire Pharma, Inc. (OCUP) and its partner Viatris Inc. (VTRS) have announced the U.S. commercial launch of RYZUMVI (phentolamine ophthalmic solution 0.75%). Ocuphire, a clinical-stage biopharmaceutical company, has a global license agreement with Viatris to co-develop and commercialize the solution, making Ocuphire eligible for regulatory and commercial milestones as well as royalties.

Portfolio Pulse from Benzinga Newsdesk

April 01, 2024 | 11:17 am

XTNT

Xtant Medical forecasts its FY2024 sales to be in the range of $112M-$116M, closely aligning with the consensus estimate of $115.95M.

Portfolio Pulse from Benzinga Newsdesk

April 01, 2024 | 11:14 am

SACH

Sachem Capital reported a Q4 EPS of $(0.05), missing the $0.11 estimate, marking a 145.45% decrease from last year. However, their sales of $16.91M exceeded the $16.58M estimate, a 6.44% increase from the previous year.

Portfolio Pulse from Benzinga Newsdesk

April 01, 2024 | 11:13 am